Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $8,614 | $6,867 | $4,977 | $4,253 |
| - Cash | $307 | $148 | $149 | $92 |
| + Debt | $17 | $17 | $20 | $25 |
| Enterprise Value | $8,324 | $6,736 | $4,848 | $4,186 |
| Revenue | $681 | $464 | $249 | $82 |
| % Growth | 46.6% | 86.4% | 204.9% | – |
| Gross Profit | $624 | $431 | $229 | $74 |
| % Margin | 91.6% | 92.7% | 91.8% | 90.2% |
| EBITDA | -$117 | -$159 | -$263 | -$285 |
| % Margin | -17.1% | -34.2% | -105.6% | -349% |
| Net Income | -$75 | -$140 | -$256 | -$284 |
| % Margin | -11% | -30.1% | -102.9% | -347.7% |
| EPS Diluted | -0.72 | -1.46 | -2.72 | -3.5 |
| % Growth | 50.7% | 46.3% | 22.3% | – |
| Operating Cash Flow | -$73 | -$124 | -$270 | -$260 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$0 |
| Free Cash Flow | -$73 | -$124 | -$271 | -$260 |